Related Experiment Video

Updated: May 23, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Structural determinants of protein kinase CK2 regulation by autoinhibitory polymerization

Graziano Lolli1, Lorenzo A Pinna, Roberto Battistutta

  • 1Department of Chemical Sciences, University of Padua, Padova, Italy. graziano.lolli@unipd.it

ACS Chemical Biology
|April 18, 2012
PubMed

Insights

Protein kinase CK2, crucial for cell life and often overactive in cancer, is regulated by an autoinhibitory mechanism. The beta-subunit drives inactive CK2 polymer formation, offering new therapeutic targets.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Biology

Background:

  • Protein kinase CK2 (CK2) is essential for cell viability.
  • Aberrantly high CK2 activity is observed in various cancers, making it a validated therapeutic target.
  • The regulatory mechanisms controlling CK2 activity remain largely unclear, unlike other kinases.

Purpose of the Study:

  • To elucidate the regulatory mechanisms of CK2 holoenzyme activity.
  • To present a novel crystal structure of the CK2 holoenzyme.
  • To investigate the role of the beta-subunit in CK2 regulation.

Main Methods:

  • X-ray crystallography to determine the structure of the CK2 holoenzyme.
  • Biochemical assays to analyze CK2 activity.
  • Functional studies to assess the role of the beta-subunit in aggregation and regulation.

Main Results:

  • A new crystal structure of the CK2 holoenzyme was determined.
  • The structure supports an autoinhibitory mechanism involving the beta-subunit.
  • The beta-subunit facilitates the formation of inactive polymeric CK2 assemblies.

Conclusions:

  • CK2 activity is regulated by an aggregation-dependent autoinhibitory mechanism.
  • The beta-subunit is critical for forming inactive CK2 polymers.
  • This provides a basis for developing novel CK2 inhibitors targeting subunit interactions.

More Related Videos

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...